Literature DB >> 16684873

Evaluating drug effects in the post-Vioxx world: there must be a better way.

Jerry Avorn.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16684873     DOI: 10.1161/CIRCULATIONAHA.106.625749

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  9 in total

1.  A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Authors:  Peter G M Mol; Sabine M J M Straus; Sigrid Piening; Jonie T N de Vries; Pieter A de Graeff; Flora M Haaijer-Ruskamp
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

2.  Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system.

Authors:  Martijn J Schuemie; David Madigan; Patrick B Ryan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

3.  Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.

Authors:  Yu Yang; Xiaofeng Zhou; Shuangqing Gao; Hongbo Lin; Yanming Xie; Yuji Feng; Kui Huang; Siyan Zhan
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

4.  Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases.

Authors:  Stephanie J Reisinger; Patrick B Ryan; Donald J O'Hara; Gregory E Powell; Jeffery L Painter; Edward N Pattishall; Jonathan A Morris
Journal:  J Am Med Inform Assoc       Date:  2010 Nov-Dec       Impact factor: 4.497

5.  Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.

Authors:  Domenico Motola; Antonio Vargiu; Roberto Leone; Anita Conforti; Ugo Moretti; Alberto Vaccheri; Giampaolo Velo; Nicola Montanaro
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Should benefit-risk assessment have its own drug "label"?

Authors:  R Scott Braithwaite
Journal:  Drug Healthc Patient Saf       Date:  2011-08-03

7.  Number of patients studied prior to approval of new medicines: a database analysis.

Authors:  Ruben G Duijnhoven; Sabine M J M Straus; June M Raine; Anthonius de Boer; Arno W Hoes; Marie L De Bruin
Journal:  PLoS Med       Date:  2013-03-19       Impact factor: 11.069

8.  The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.

Authors:  John S Brownstein; Margarita Sordo; Isaac S Kohane; Kenneth D Mandl
Journal:  PLoS One       Date:  2007-09-05       Impact factor: 3.240

9.  Premarket safety and efficacy studies for ADHD medications in children.

Authors:  Florence T Bourgeois; Jeong Min Kim; Kenneth D Mandl
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.